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Pore-forming proteins containing the structurally
conserved membrane attack complex/perforin fold
play an important role in immunity and host-path-
ogen interactions. Intermedilysin (ILY) is an arche-
typal member of a cholesterol-dependent cytolysin
subclass that hijacks the complement receptor
CD59 to make cytotoxic pores in human cells. ILY
directly competes for the membrane attack complex
binding site on CD59, rendering cells susceptible to
complement lysis. To understand how these bacte-
rial pores form in lipid bilayers and the role CD59
plays in complement regulation, we determined the
crystal structure of human CD59 bound to ILY.
Here, we show the ILY-CD59 complex at 3.5 A˚ reso-
lution and identify two interfacesmediating this host-
pathogen interaction. An ILY-derived peptide based
on the binding site inhibits pore formation in a
CD59-containing liposome model system. These
data provide insight into how CD59 coordinates ILY
monomers, nucleating an early prepore state, and
suggest a potential mechanism of inhibition for the
complement terminal pathway.
INTRODUCTION
Bacterial toxins of the cholesterol-dependent cytolsysin (CDC)
superfamily form pores in lipid bilayers through the oligomeriza-
tion of their membrane attack complex/perforin fold (MACPF)
domain. CDCs are produced by over five different genera of
Gram-positive bacteria, resulting in a wide range of animal and
human diseases (Tweten et al., 2001). Intermedilysin (ILY) is a
CDC secreted by Streptococcus intermedius that causes brain
and liver abscesses in its host (Nagamune et al., 1996) and is
thought to be the major virulence factor for the bacterium (Naga-
mune et al., 1996). Cholesterol is essential for ILY cytolytic activ-
ity, and crystal structures of ILY and other CDCs show strong
structural homology (Bourdeau et al., 2009; Polekhina et al.,
2005; Rossjohn et al., 1997; Rossjohn et al., 2007; Xu et al.,C2010). Most CDCs bind to cholesterol-rich membranes via a
cholesterol recognition motif (CRM) and neighboring undeca-
peptide. This binding triggers the oligomerization and allosteric
regulation of the transition to the pore state (Dowd and Tweten,
2012). ILY, on the other hand, has evolved to recruit the human
complement regulator CD59 as a receptor providing the basis
for its species specificity (Giddings et al., 2004). It is CD59-bind-
ing that promotes both oligomerization of ILY monomers on the
cell surface (LaChapelle et al., 2009) and the structural rear-
rangements required for pore formation (Dowd and Tweten,
2012). In contrast, the interaction of cholesterol with the CRM
and undecapeptide is required for the maintenance of the ILY
prepore at the membrane as CD59 is released (LaChapelle
et al., 2009). Mutational analysis of ILY has determined residues
involved in both lipid and receptor binding (Wickham et al., 2011)
aswell as those crucial for mediating structural transitions (Dowd
and Tweten, 2012; Hotze et al., 2012; LaChapelle et al., 2009;
Soltani et al., 2007a, b). Our structure of the ILY-CD59 complex
now provides a framework with which to integrate these
biochemical and biophysical data.
CD59 is the only membrane-bound inhibitor of the comple-
ment terminal pathway (Meri et al., 1990). This small (77 amino
acid) GPI-anchored cell-surface receptor binds complement
components C8 and C9 (Ninomiya and Sims, 1992) and directly
inhibits the formation of the membrane attack complex (MAC),
an immune pore that kills microbes by the disruption of lipid
bilayers. CD59 is expressed on a variety of cell types, including
leukocytes, epithelial, and endothelial cells (Meri et al., 1991)
and plays an important role in preventing complement-mediated
tissue damage in hosts. CD59 has been implicated in a number
of human diseases, including tumor cell evasion during mono-
clonal antibody treatments (Fishelson et al., 2003; Gorter and
Meri, 1999) and paroxysmal nocturnal hemoglobinuria (Hill
et al., 2006). Structural studies of soluble CD59 (Fletcher et al.,
1994; Kieffer et al., 1994; Leath et al., 2007) and direct binding
assays of CD59 with complement components (Huang et al.,
2006) have provided some insight into the role of this receptor
in regulating MAC assembly. However, a lack of structural infor-
mation characterizing CD59 with its binding partners has limited
our ability to control complement susceptibility.
Here, we report the crystal structure of CD59 bound to ILY, a
bacterial toxin that directly competes for MAC binding. Weell Reports 3, 1369–1377, May 30, 2013 ª2013 The Authors 1369
Figure 1. Structure of the ILY-CD59 Complex
(A) Two views of the complex related by 90. The protein is shown in cartoon representation and colored by domain. ILY-D1, blue; ILY-D2, yellow; ILY-D3, green;
ILY-D4, red; and CD59, gray.
(B) A view of the crystal packing at the ILY-CD59 interface. ILY D1–D3 are shown as drawings and colored as in (A). ILY-D4 is colored red and shown as a drawing
with a transparent surface. CD59 is colored gray and shown as a drawing with a transparent surface. A neighboring copy of the complex from the next unit cell is
also shown with ILY rendered as a transparent drawing, and CD59 is shown in a light gray drawing with a transparent surface.
(C–D) Zoom on the two ILY-CD59 interfaces in the crystal colored as in (B). Residues on CD59 and ILY that impact binding and function when mutated are shown
in ball and stick and colored green and purple, respectively.
Figures were rendered with PyMOL. See also Figure S1.define two interfaces on CD59 that coordinate ILY monomers
and validate this interaction through the development of a lipo-
some-based model system. Cholesterol-containing liposomes
decorated with cytotopic CD59 capture ILY monomers and sup-
port pore formation in a fluorescence-based assay. We also find
that an ILY-derived peptide based on our structure disrupts the
interface and competes for pore formation. In addition, cryo-
electron microscopy (cryo-EM) images of the crystallized ILY
mutant bound to CD59-decorated liposomes suggest that the
linear arrays observed in our crystal could also occur in the
context of a membrane. Altogether, our structural and functional
data provide mechanistic insight into how CD59 engages ILY for
the formation of a pore in lipid bilayers, providing a basis for the
development of new antibiotics as well as potential therapeutics
that target CD59.1370 Cell Reports 3, 1369–1377, May 30, 2013 ª2013 The AuthorsRESULTS
Crystal Structure of the ILY-CD59Complex Reveals Two
Interfaces
An early prepore intermediate comprising the initial attachment
of ILY to CD59 was captured with a disulfide-locked ILY mutant
(ILYEPP) and a CD59 construct lacking the GPI anchor. Both
proteins were expressed and purified independently. The com-
plex was assembled in vitro, subjected to further purification,
and crystallized. The crystals diffracted to a resolution of
3.5 A˚, and the structure was solved by molecular replacement.
The final model, consisting of all four domains of ILY and
the ectodomain of CD59, was refined to a final Rwork/Rfree
of 21.2%/26.6% and displayed good geometry (Figures 1
and S1A; Table 1).
Table 1. Data Collection and Refinement Statistics
ILYEPP/CD59
Space group P1
Unit cell parameters (A˚) a = 27.4, b = 101.45, c = 112.88,
a = 63.75, b = 89.95, g = 90.02
Resolution (A˚) 45.45-3.49 (3.62-3.49)
No. unique reflections 13247 (1303)
Rmerge 0.111 (0.304)
I/s (I) mean 7.3 (2.0)
Completeness (%) 96.0 (96.9)
Multiplicity 2.0 (2.0)
Rwork /Rfree 0.212/0.266 (0.239/0.267)
No. atoms
Protein 8387
Ligand/ion 0
Water 0
Mean B factors (A˚2) 103.00
RMSDs
Bond lengths (A˚) 0.004
Bond angles () 0.96
Ramachandran plot analysis
Most favored regions (%) 95.0
Disallowed regions (%) 0.2
Molprobity score 2.28
PDB code 4BIK
Numbers in brackets refer to the highest resolution shell.As described previously, ILY is comprised of four structural
domains, the first three of which are formed from discontinuous
stretches of sequence. Domain 1 (D1) (residues 56–76, 117–201,
258–299, and 379–399) forms a cap at the top of the molecule
and is the least well-ordered region of our crystal (Figure S1B).
Domain 2 (D2) (residues 77–116 and 400–417) consists of three
kinked b strands that span 50 A˚ and bridge domains 1 and 4.
Domain 3 (D3) (residues 202–257 and 300–378) packs against
D2 and contains the helical bundles that are predicted to refold
into transmembrane b-hairpins. This domain, along with D1,
makes up the MACPF domain and also contains the site of the
engineered disulfide bond (C346-C361) that prevents the struc-
tural rearrangements required for full pore formation. Finally,
domain 4 (D4) (residues 418–528) is a discrete b sandwich struc-
ture extending from the end of D2. CD59 is a compact, heavily
disulfide-bonded structure with a central b sheet bookended
by a short a helix and a two-strand b hairpin.
The asymmetric unit of the crystal contains two copies of the
ILY-CD59 complex, which overlay with an RMSD of 1.0 A˚ over
530 residues. CD59 predominantly interacts with D4 of ILY (Fig-
ure 1A), which is in agreement with previous studies (Nagamune
et al., 2004; Polekhina et al., 2005). Strikingly, there are twomajor
ILY-CD59 interfaces within the crystal: one within the asym-
metric unit and one between neighboring unit cells (Figure 1B).
The primary ILY-CD59 binding site (665 A˚2 buried surface area)
is composed of a side-to-side contact between the b hairpinCextension of ILY D4 (the b2-b3 loop) and the core b sheet of
CD59 (Figure 1C), effectively creating an extension of the CD59
sheet. The interface is further stabilized by the stacking of hydro-
phobic side-chains (ILY:Y436, ILY:I450, CD59:F47, CD59:Y61,
and CD59:F42) as well as an extensive network of hydrogen
bonds (both sidechain-sidechain and sidechain-backbone)
and salt bridges (ILY:R480, CD59:E58; ILY:448, CD59:K65;
ILY:D445, and CD59:K66). This interface is supported by two in-
dependent mutagenesis studies (Hughes et al., 2009; Wickham
et al., 2011). Specifically, ILY double (Y434A/Y436A) and triple
(S499N/K500R/N501T) mutants located within our primary
CD59 interface (Figure 1C) dramatically inhibited pore formation
and decreased the affinity of ILY for CD59. In addition, double-
and single-point mutations in CD59 have implicated aromatic
residues that map to this interface (F42, F47, and Y62) as being
involved in ILY binding (Wickham et al., 2011).
The secondary binding site is formed by the same region of ILY
(the b2-b3 loop in D4) interacting with CD59 from a neighboring
unit cell. This interface buries 500 A˚2 and is stabilized by a series
of hydrogen bonds and three salt bridges (ILY:D443, CD59:R55;
ILY:D445, CD59:K38; ILY:E93, and CD59:K41). The second
interface is again validated by previous mutagenesis studies of
both ILY and CD59 (Wickham et al., 2011). In particular, a double
mutation in ILY (R451A/S452A) that reduces CD59-binding and
hemolysis maps to this region (Figure 1D). CD59 mutations
D22 and F23, also located in this interface (Figure 1D), play a
role in ILY binding and function. Therefore, CD59 displays two
distinct binding sites for ILY that can be simultaneously occu-
pied. This suggests that, in addition to localizing ILY to the mem-
brane surface, CD59 helps nucleate an early prepore complex by
bridging neighboring ILY molecules, thereby creating the linear
array observed in our crystals.
Probing the ILY-CD59 Interfaces within the Context
of a Cholesterol-Containing Membrane
To address the functional significance of the ILY-CD59 inter-
faces observed in our crystal structure, we developed a simple
model membrane system to probe ILY pore formation in a fluo-
rescence-based assay (Koc¸er et al., 2007). Calcein-containing
liposomes were decorated with soluble CD59 and modified to
possess a myristoylated lysine-rich ‘‘cytotopic’’ peptide (Fraser
et al., 2003). Lipid attachment of cytotopic CD59 was confirmed
by the colocalization of protein in lipid-containing fractions
across a Ficoll gradient (Figure 2A). The fluorescence intensity
of calcein released from liposomes upon lysis was used to deter-
mine the rate of pore formation. Exposure of wild-type ILY
(ILYWT) with cholesterol-containing CD59-decorated liposomes
resulted in functional transmembrane pores (Figure 2B), whereas
undecorated liposomes did not support lysis (Figure 2B).
Furthermore, incubation of liposomes with cytoptic CD59 alone
did not leak calcein (Figure 2B). To confirm binding of the ILY b
hairpin extension to CD59, a peptide comprised of ILY residues
438–452 was synthesized with bridging N- and C-terminal
cysteines. CD59-containing liposomes were incubated with
increasing concentrations of peptide and subjected to ILY lysis.
The peptide successfully competed for CD59 binding and
inhibited ILY pore formation with an IC50 of approximately
25 mM (Figures 2C and S2).ell Reports 3, 1369–1377, May 30, 2013 ª2013 The Authors 1371
Figure 2. ILY Pore Formation in a Model
Membrane System
(A) Cytotopic (top) and soluble CD59 (bottom)
were incubated with liposomes and subjected to
flotation through Ficoll (0%–20%). Gradients were
fractionated from the top and aliquots run on
Coomassie-stained SDS-PAGE gels. Lissamine
rhodamine B-labeled liposomes banded at
fractions 3 and 4. M, molecular weight markers.
Arrows indicate the position of CD59 on the gel.
(B) Calcein-containing liposomes were incubated
with either cytotopic CD59 (red), ILYWT (blue), or
both proteins (black). The fluorescence due to
calcein released from liposomes wasmeasured as
a function of time. The background was sub-
tracted from the fluorescence intensity, and this
was normalized according to the maximum in-
tensity obtained after treatment with detergent.
Error bars indicate the SD in normalized fluores-
cence intensity over three independent experi-
ments. The average curve was fitted (green) with a
nonlinear fitting algorithm (OriginPro 8.6), and a
rate constant of 6.74 ± 0.13 min was determined.
(C) Lytic activity of ILY in the presence of
increasing concentrations of peptide expressed
as a percentage relative to wild-type ILY. Each
sample was tested in three different experiments.
SEs are indicated.
See also Figure S2.To understand how CD59 coordinates ILY monomers to form
the pore, we characterized the complex in a lipid environment
using electron microscopy. Because negatively stained speci-
mens could lead to distortions of liposome curvature and
possible liposome collapse, we used cryo-EM to visualize mem-
brane-bound complexes. Examination of cryo-EM fields of
ILYWT-CD59-liposome complexes revealed a population of lipo-
somes with multiple instances of embedded circular pores (Fig-
ure 3A). Density is clearly visible for the ILYWT protein rings with
obvious disruption to the lipid bilayer. The diameter of the ILYWT
pore is approximately 300 A˚, consistent with the dimensions pre-
viously reported for other CDC and perforin pores (Law et al.,
2010; Tilley et al., 2005). To test the ability of the crystallized
ILY mutant (ILYEPP) to form linear arrays in the context of a mem-
brane, we examined two-dimensional cryo-EM images of the
mutant form bound to CD59-decorated liposomes (Figure 3B).
As expected, no perforation of the lipid bilayer was observed
with this prepore intermediate. Protein density on the periphery
of liposomes appears to be organized in linear clusters; however,
due to the fragility of the system, we were unable to collect
in-plane images to confirm this. Reversible linear arrays of a pre-
pore-trapped mutant form of perfringolysin have demonstrated
that CDCs undergo transient, yet specific, intermolecular inter-
actions that precede ring closure (Hotze et al., 2012). These
data suggest that the linear organization of ILY-CD59 complexes
observed in our crystal structure is relevant for understanding
how ILY engages with CD59 in the context of a membrane.
Model for the ILY Early Prepore
Previously reported cryo-EM reconstructions of the pneumolysin
prepore and pore structures have provided a model for how1372 Cell Reports 3, 1369–1377, May 30, 2013 ª2013 The AuthorsCDCs oligomerize on membranes (Tilley et al., 2005). Preserving
the two ILY-CD59 interfaces observed in our crystal structure,
we used this as a starting point to turn the linear array of our lat-
tice into amodel for the ILY early prepore state (see Experimental
Procedures for details). This arrangement places CD59 at the
periphery of the ring (Figure 4), and we find that the presence
of CD59 would not obstruct ILY oligomerization, in concordance
with data showing that CD59 remains bound during prepore
assembly (LaChapelle et al., 2009). These data, along with the
high concentration of CD59 on the cell surface (Anstee, 1990),
have led us to include CD59 in our model of an ILY prepore olig-
omeric ring. The subsequent release of CD59 during the pore
transition, observed previously by biophysical studies (LaCha-
pelle et al., 2009), could be due in part to conformational
changes that are incompatible with maintaining CD59 in the
complex. In our model, the C-terminal residue of CD59 preced-
ing the GPI anchor is positioned approximately 15 A˚ from the
plane of the membrane (Figure 4). This observation is consistent
with distances measured for other GPI-anchored proteins (Lehto
and Sharom, 2002) and with a model previously proposed for
CD59 glycosylation (Rudd et al., 1997). Therefore, our structural
and functional data together suggest that the role of CD59 in ILY
pore formation is to orient the ILYCRMand undecapeptide prox-
imal to cholesterol-containing lipid bilayers and to propagate ILY
monomer-monomer interactions through two binding interfaces.
DISCUSSION
Structural studies of CDCs (Bourdeau et al., 2009; Polekhina
et al., 2005; Rossjohn et al., 1997; Rossjohn et al., 2007; Xu
et al., 2010) and components of the complement MAC (Aleshin
Figure 3. CD59 Coordinates ILY Monomers
to Form the Pore
(A) A cryo-EM image of ILYWT pores formed on
CD59-decorated liposomes. Black arrows indi-
cate sites of bilayer disruption. The scale bar
represents 100 nm.
(B) A cryo-EM image field of the crystallized
mutant form of ILY (ILYEPP) bound to CD59-
decorated liposomes. ILYEPP clusters on the sur-
face of liposomes are highlighted within boxes.
The scale bar represents 100 nm.et al., 2012; Hadders et al., 2007; Hadders et al., 2012; Lovelace
et al., 2011) reveal that the fundamental pore-forming mecha-
nism of these MACPF-containing proteins are similar. Both
involve the conversion of water-soluble proteins to transmem-
brane oligomeric pores. However, within this conserved mecha-
nism, one of the most important differences remains in its
regulation. For many CDCs, membrane binding by the CRM
and undecapeptide initiates structural transitions (Dowd and
Tweten, 2012), which are propagated between membrane-
bound monomers (Hotze et al., 2012). Circularization of the
CDC oligomeric ring then triggers a dramatic conformational
change in which helical segments from D3 convert to amphi-
pathic hairpins and arrange into a transmembrane b-barrel
pore (Tilley et al., 2005). For a subclass of CDCs, of which ILY
is an archetypal member, control of regulating prepore transi-
tions is transferred from the undecapeptide to CD59 binding
(Dowd and Tweten, 2012).
Our structural and functional analysis of the ILY-CD59 com-
plex supports a model for these pores in which membrane-
anchored CD59 recruits soluble ILY monomers to the plasma
membrane of human cells, orienting the CRM and undecapep-
tide for insertion into cholesterol-containing lipid bilayers.
Through two distinct ILY-binding interfaces on opposite sides
of the molecule, CD59 brings together ILY monomers in order
to facilitate intermolecular interactions that drive the formation
of an oligomeric prepore ring. Relatively small alterations to the
packing of our crystal lattice produces a 31-fold symmetric
model for this early prepore state that agrees with a pneumolysin
prepore model (Tilley et al., 2005). Even smaller manipulations of
our lattice produce alternate models for ILY pores in line with theCell Reports 3, 1369–137proposed stoichiometries observed for
other CDCs by different biophysical tech-
niques (31- to 44-fold) (Czajkowsky et al.,
2004; Tilley et al., 2005).
Monomer-monomer interactions of
CDCs have been shown to propagate
early structural transitions required for
pore formation (Hotze et al., 2012). Spe-
cifically, the positioning of neighboring
molecules has been suggested to allow
the intermolecular pairing of b1 from D3
of one molecule with b4 from the equiva-
lent domain of the next. Analysis of the
impact of applying curvature to our linear
array shows that these contacts areindeed partially formed in our model (Movie S1). In order to com-
plete the zippering of the sheet-formation, b5 would need to
swing out of the way. This transition is prevented in our crystal
by the engineered disulfide bond in ILYEPP locking b5 to b4,
thus trapping the earliest prepore state.
Although ILY andMACcomponents (C8 andC9) all bindCD59,
the result of this interaction has profoundly different outcomes on
pore formation. Although CD59 promotes the oligomerization of
ILY monomers (LaChapelle et al., 2009), the receptor inhibits
MAC formation by preventing membrane perforation and incor-
poration of multiple C9 molecules (Farkas et al., 2002; Meri
et al., 1990; Rollins and Sims, 1990). ILY directly competes for
theMAC binding site on CD59 (LaChapelle et al., 2009; Wickham
et al., 2011), and amutational analysis has confirmed that the ILY
andMAC binding sites on the surface of CD59 overlap, at least in
part (Bodianet al., 1997;Huanget al., 2005;Wickhamet al., 2011).
CD59-bindingMAC components lack the structural equivalent of
ILY D4, therefore precluding further insight into how specific res-
idues of C8 and C9 interact with the complement receptor. How-
ever, it is possible that CD59 engages the transmembrane seg-
ments of complement components after their transition to b
hairpins but prior tomembrane insertion, similar to the interaction
of CD59 with the b hairpin extension of ILY D4. It is interesting to
note that the residues on CD59 involved in MAC binding map to
the same two opposing faces observed in our ILY interaction.
CD59 inhibits MAC assembly most efficiently when incorporated
prior to the addition ofC9 (Lehto andMeri, 1993). Subsequently, it
appears to lock a singleC9molecule into the complex in a confor-
mation that prevents membrane perforation and further C9
recruitment (Lehto and Meri, 1993; Meri et al., 1990). These7, May 30, 2013 ª2013 The Authors 1373
Figure 4. Model for ILY Pore Formation
(A) Soluble ILY (blue ribbons) targets human cell membranes by binding GPI-anchored CD59 (yellow ribbons). Modeling of CD59 glycosylation reveals that
binding is not obstructed by sugars (orange sticks) and that the ILY undecapeptide loop (red) is positioned proximal to the plane of the membrane (gray slab).
CD59 GPI anchor is shown in light green.
(B) CD59 coordinates ILY monomers on the membrane through two distinct interfaces, nucleating an early prepore state.
(C–D) Circularization of the linear array observed in our crystal structure maintains these two interfaces and suggests that CD59 binds on the periphery of the
oligomeric ring.
(C) Cross-section through the prepore oligomer.
(D) Full oligomeric ring.
Figures were rendered with PyMOL. See also Movie S1.observations, along with the ILY-CD59 crystal structure, suggest
a mechanism for MAC inhibition whereby CD59 intercalates be-
tween C8 and C9 in an analogous manner to the ILY nucleation,
locking the MAC in a nonfunctional state.
In summary, our findings providemechanistic insights into how
ILY pores form, revealing a dual role of CD59 in facilitating the
assembly of the oligomeric prepore. Our structural and functional
data have defined twoCD59-ILY interaction interfaces, providing
a framework for the development of new antibiotics and CD59-
targeted therapeutics that could improve human health.EXPERIMENTAL PROCEDURES
Expression and Purification of the ILY-CD59 Complex
RecombinantsolublehumanCD59withanadditionalC-terminal cysteine residue
was expressed in E.coli, refolded, and purified from solubilized inclusion bodies
asdescribedpreviously (Leathetal., 2007).PurifiedCD59 (approximately0.5mM
in phosphate-buffered saline [pH7.3] PBS) was treated for 16 hr at ambient tem-
perature with two molar equivalents of tris-2-carboxyethyl phosphine (TCEP,
Sigma-Aldrich) for the generation of a free thiol at the carboxyl terminal cysteine
of the protein. This was incubated for 2 hr at ambient temperature with a 3-fold
molar excess of the cytotopic modification reagent bis-myristoyl lysyl
SSKKSPSKKDDKKPGD (S-2-thiopyridyl)-cysteine acid (APT3146, Cambridge
Research Biochemicals) for the generation of cytotopic CD59 (Hill et al., 2006).
CytotopicCD59was further purifiedbyhydrophobic interactionchromatography
and ammonium sulfate precipitation. The main protein peak fractions were
pooled, buffer exchanged into PBS, and stored at –70C until use.1374 Cell Reports 3, 1369–1377, May 30, 2013 ª2013 The AuthorsAn ily gene lacking cysteine residues (ILYWT) and a disulfide-locked ily
mutant containing the substitutions T346C and I361C (ILYEPP) were cloned
into a pTrcHisA vector and were generous gifts from R. Tweten. This early pre-
pore form of ILY was characterized previously (LaChapelle et al., 2009) and
shown to be converted to functional pores by the addition of reducing agent.
Recombinant ILY proteins were expressed in Rosetta-2 cells (Novagen). Cells
were grown to an optical density of 0.6 at 37C and induced with 0.5 mM IPTG
for 4 hr. Cultures were pelleted and lysed in a buffer containing 1% Triton,
200 mM NaCl, 20 mM Tris (pH 6.8), Protease Inhibitor Mixture (Sigma-Aldrich,
50 ml per gram of cell pellet), 100 mg of DNase I, and 100 mg of RNase A (Sigma-
Aldrich). Cleared lysates were loaded onto cobalt-chelated TALON beads
(Clontech) and eluted with 500 mM imidazole. ILY was further purified by
size exclusion chromatography in 150 mM NaCl and 20 mM Tris (pH 6.8).
ILY and CD59 were incubated at room temperature in a 1:2 molar ratio, and
the complex was separated on a Superdex 200 HR 10/30 column (Pharmacia
Biotech).
Crystallization and Data Collection
Crystals were grown by vapor diffusion at room temperature in 96-well plates
with 0.4 ml droplets at 21C. Equal volumes of preformed ILYEPP-CD59 com-
plex (9.9 mg/ml in 150 mm NaCl, and 20 mM Tris [pH 6.8]) and precipitant
(20% PEG6000, 0.1 M HEPES [pH 7], and 0.2 M LiCl) were mixed. Crystals
were cryo-protected with reservoir solution plus 20% glycerol before cryo-
cooling in liquid nitrogen. Data were collected at Diamond Light Source (Har-
well Science and Innovation) at beamline I04.
Structure Determination and Refinement
Diffraction data were processed with xia2 (Winter, 2010) in 3diir mode and
initially assigned as P21 with a single copy of the complex per asymmetric
unit (indexing initially suggested C222 (1), but this failed upon scaling, see the
twinning discussion below). The structure of the ILY-CD59 complex was
solved by molecular replacement with the use of Phaser (McCoy et al.,
2007). A solution was reached with the use of the known structures of ILY
(PDB 1S3R) (Polekhina et al., 2005) and CD59 (PDB 2UWR) (Leath et al.,
2007), with the ILY split into two search models encompassing D1–D3 and
D4. Analysis of the data with Xtriage (Adams et al., 2010) suggested that the
data were twinned, and the structure was refined with Phenix (Adams et al.,
2010) with the pseudomerohedral twinning operator (h,-k,-h-l; twin fraction =
0.08) modeled. Analysis of the resultant maps showed poor density for large
stretches of D1 with no extra density or residuals, and the Rfree did not drop
below 0.30. Therefore, we reprocessed the data in P1 (xia2, 3da mode) and
resolved the structure with two copies of the complex in the asymmetric
unit. Analysis of the P1 data set with Xtriage suggested twinning with only
one of the three possible pseudomerohedral twinning operators (h,-k-l) signif-
icantly occupied (twin fraction = 0.46). Although the data merge well to 3.5 A˚ in
both P21 (Rpim = 0.077, Rmerge = 0.105) and P1 (Rpim = 0.098, Rmerge = 0.111),
refinement carried out in the P1 data set in Phenix with the h,-k,-l operator
modeled produced lower R factors than the P21 refinement. After rebuilding
in Coot (Emsley et al., 2010), the Rwork/Rfree converged to 0.212/0.266
(compared to 0.248/0.300 for the same model in the P21 data). Furthermore,
the P1maps showed clear features that differed between the two independent
copies of the complex—in particular, the engineered disulfide (Cys346-
Cys361) was clearer in one copy—and the pattern of thermal motion factors
over the two molecules reproducibly refined to different distributions. Some
stretches of D1 still hadweak or no electron density associated with themodel,
although this varied between the two copies. However, refinement statistics
worsen when these regions are removed, and molecular replacement of this
domain placed it with Z score > 15 in Phaser. Therefore, we decided to refine
D1 in place and not rebuild in the density. The final refined P1model gave good
MolProbity statistics for the resolution (MolProbity score = 2.28, 99th percen-
tile). Running Xtriage with the final refined model in P1 gave R versus R statis-
tics (Lebedev et al., 2006) for the h,-k,-l operator of 0.132/0.373 (Robs/Rcalc),
consistent with twinning with rotational pseudosymmetry.
Building a Model of the Early Prepore
Amodel for an early prepore was generated from the crystal lattice by bending
a linear array containing 31 copies of the 1:1 ILY-CD59 complex into a circle. In
brief, the linear array was placed onto the deposited pneumolysin prepore
model (PDB 2BK2) by the superposition of D1–D3 with secondary structure
mapping (lsqkab). Then, a 15.3 rotation was applied to make the linear array
tangential to the circular prepore density (EMDB 1106). The linear array was
then bent into the circular form by the application of a 0, 0, 11.6 rotation
(polar angles) to a monomer. The CD59 N-linked glycan on Asn18 and the
GPI anchor were modeled with the coordinates described in Rudd et al.,
1997, and kindly supplied by M. Wormald.
Preparation of Liposomes
1,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS), 1,2-dioleoyl-sn-glycero-
3-phosphoethanolamine (DOPE), 1,2-dioleoyl-sn-glycero-3-phosphocholine
(DOPC), and cholesterol (supplied in chloroform from Avanti Polar Lipids)
weremixed inmolar ratios of 3:3:2:2, respectively. Chloroformwas evaporated
with a stream of nitrogen gas, leaving a thin lipid film. Dried lipid was rehy-
drated with four freeze, thaw, and vortex cycles followed by extrusion through
a 0.1 mm pore-size membrane (Avanti) for the formation of a homogeneous
population of unilamellar liposomes, freshly prepared for each experiment.
Fluorescently-labeled liposomes were generated by in the inclusion of
50 mM calcein (Sigma-Aldrich) in the rehydration buffer. This initial calcein
concentration of 50 mM is sufficient to cause almost complete self-quenching
of its fluorescence; if calcein is subsequently released from the liposomes, its
concentration is reduced and an increase in fluorescence is observed. Unen-
capsulated dye was removed by passage through a G-50 Sephadex column
(Sigma-Aldrich) run in a buffer containing 500 mM sucrose.
Lipid Flotation Assay
Lipids were tracked by the inclusion of phosphatidylethanolamine with liss-
amine rhodamine B-labeled head groups (Avanti) in the lipid mixture describedCabove at a final concentration of 2% (w/w) prior to the evaporation of chloro-
form. Extruded liposomes at a concentration of 1 mg/ml were incubated
with either soluble or cytotopic CD59 at a final concentration of 18 mM. The
liposome sample was adjusted to contain Ficoll at a final concentration of
20% (w/v) and was overlaid with 10% (w/v) Ficoll followed by buffer alone. Af-
ter centrifugation at 100,000 3 g at 20C for 45 min, gradients were fraction-
ated from the top. Fractions were analyzed for the presence of liposomes by
the visualization of rhodamine and for the presence of CD59 by SDS-PAGE
and Coomassie staining.
Fluorescence-Based Liposome Lysis Assay
Pore-formation assays were performed at 20C in a Varian Cary Eclipse Fluo-
rescence Spectrophotometer (Agilent Technologies) with excitation and emis-
sion wavelengths of 490 nm and 520 nm, respectively, and a slit width of 5 nm.
The kinetics mode of the spectrophotometer was used with an average read
time of 0.15 s, and measurements were made every minute. A peptide corre-
sponding to the CD59-binding interface of ILY (residues 438–452) was synthe-
sized with bridging N- and C-terminal cysteines (CEELGHDADGYETIRSC)
(Severn Biotech). Cytotopic CD59 at a final concentration of 0.7 mM was incu-
bated with 200 ml of fluorescently-labeled liposomes in the presence or
absence of peptide, and the average background fluorescence intensity was
measured for 10 min. Subsequently, ILYWT at a final concentration of 0.7 mM
was added to the reaction and the fluorescence was measured for 45 min.
Liposomes were burst at the end of the experiment by the addition of 1 ml
0.2M C12E8 detergent (Sigma-Aldrich), and the maximum fluorescence was
found by monitoring the sample for an additional 10 min. The fluorescence
measurements for each reaction were normalized according to the back-
ground and detergent readings. Rates of calcein release (which corresponds
to pore formation) were calculated by fitting the normalized fluorescence inten-
sity data with a nonlinear fitting algorithm in OriginPro 8.6.
Cryo-Electron Microscopy
We incubated 0.75 mg ml1 liposomes with cytotopic CD59 and either ILYWT
or ILYEPP in equimolar ratios so that the final protein concentration was
1 mg/ml. We applied 2.5 ml of the mixture to glow discharged holey carbon
grids (QUANTIFOIL R 2/2) and vitrified in liquid ethane with an FEI Vitrobot.
Images were acquired on a CM200 FEG electron microscope (FEI) operating
at 200 kV. Images were recordedwith a defocus range of2.5 to3.5microns
underfocus at a magnification of 38,0003 and an electron dose of 20 e/A˚2
with a 4k 3 4k TemCam-F415MP CCD camera (Tietz Video and Image Pro-
cessing Systems).
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